Also, an anti-CD33 nanobody which was developed for targeting AML cells (30), could be used instead of anti-CD33 scFv in CD16(scFv)/IL-15/CD33(scFv) TriKE. This evidence concerns the gene IL15 and acute myeloid leukemia.